or Try an Advanced Search...

    Technical Analysis for BIAF - bioAffinity Technologies, Inc.

    Grade Last Price % Change Price Change
    F 1.37 -4.20% -0.06
    BIAF closed down 4.2 percent on Friday, November 1, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BIAF trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -4.20%
    Narrow Range Bar Range Contraction -4.20%
    Wide Bands Range Expansion -4.20%
    Oversold Stochastic Weakness -4.20%
    Older End-of-Day Signals for BIAF ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Down 5% about 21 hours ago
    10 DMA Support about 23 hours ago
    Down 3% 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    BIAF Chart by TradingView
    Basic chart:

    Profile

    bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Biotechnology Cancer Life Sciences Biology Lung Cancer Molecular Diagnostics Diagnostic Tests Cancer Therapeutics

    Is BIAF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 30 bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
    Oct 21 WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
    Oct 21 bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
    Oct 18 WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
    Oct 18 bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
    Oct 16 bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
    Oct 10 bioAffinity Technologies names J. Michael Edwards as CFO
    Oct 10 bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
    Oct 9 bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
    Sep 18 Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
    See more BIAF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.62
    52 Week Low 1.25
    Average Volume 132,745
    200-Day Moving Average 2.01
    50-Day Moving Average 1.70
    20-Day Moving Average 1.64
    10-Day Moving Average 1.39
    Average True Range 0.17
    RSI (14) 39.76
    ADX 27.0
    +DI 14.84
    -DI 29.51
    Chandelier Exit (Long, 3 ATRs) 1.73
    Chandelier Exit (Short, 3 ATRs) 1.77
    Upper Bollinger Bands 2.23
    Lower Bollinger Band 1.05
    Percent B (%b) 0.27
    BandWidth 72.00
    MACD Line -0.14
    MACD Signal Line -0.11
    MACD Histogram -0.0298
    Fundamentals Value
    Market Cap 13.02 Million
    Num Shares 9.5 Million
    EPS -0.43
    Price-to-Earnings (P/E) Ratio -3.19
    Price-to-Sales 46.70
    Price-to-Book 2.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.46
    Resistance 3 (R3) 1.46 1.44 1.45
    Resistance 2 (R2) 1.44 1.41 1.44 1.44
    Resistance 1 (R1) 1.40 1.40 1.39 1.40 1.43
    Pivot Point 1.38 1.38 1.37 1.38 1.38
    Support 1 (S1) 1.34 1.35 1.33 1.34 1.31
    Support 2 (S2) 1.32 1.34 1.32 1.30
    Support 3 (S3) 1.28 1.32 1.30
    Support 4 (S4) 1.28